Release Date: December 20, 2023
Expiration Date: December 20, 2024

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Despite the significant advances in understanding myelofibrosis (MF) pathophysiology and outcomes attributed to JAK inhibitors, challenges remain in the development of treatment plans tailored for the individual patient. Join our program on the development and optimization of individualized treatment strategies for MF patients in the real-world clinical practice setting.

Target Audience

This activity is designed for community-based hematologists, hematologist/oncologists and community-based advanced practice providers in hematology/oncology who provide care to patients with myelofibrosis.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Outline strategies for effectively and accurately diagnosing MF and for stratifying MF patients according to risk
• Correlate safety and efficacy data for new and emerging therapies in MF with patient types and clinical scenarios most appropriate for each
• Identify treatment emergent adverse events (TEAEs) associated with therapeutic options for MF and outline proactive clinical strategies for minimizing and/or mitigating these TEAEs if and when they develop
• Identify strategies for developing optimized, tailored treatment plans for individual patients with MF

Agenda

Strategies for Improving Patient Outcomes in Myelofibrosis – Jeanne Palmer, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 20, 2024. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biography

Jeanne Palmer, MD
Associate Professor
Section Head of Hematology
Director, Blood and Marrow Transplant Program
Mayo Clinic
Phoenix, Arizona

Dr. Jeanne Palmer is an Associate Professor of Medicine at Mayo Clinic in Phoenix AZ. In addition, she also serves as the Section Head of Hematology, and is the Director of the Blood and Marrow Transplant Program at Mayo Clinic Arizona.

Dr. Palmer is involved in the care of patients with myeloproliferative diseases, offering clinical trials for patients with myeloproliferative diseases, as well as bone marrow transplants for patients with myelofibrosis. She has been involved in numerous clinical trials and research efforts.

She believes in individualized care of patients with myeloproliferative disorders, addressing the medical issues associated with these diseases as well as the symptom burden.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	NURSING CREDIT MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-012-169

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Jeanne Palmer, faculty for this educational activity, has relevant financial relationships related to research from Celgene Corporation ‒ A Bristol Myers Squibb Company (relationship has ended), MorphoSys AG, PharmaEssentia, Protagonist, and Sierra Oncology, Inc. (now GSK plc).

All of the relevant financial relationships listed for this individual have been mitigated prior to this activity.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, and Cassie Rametta, Senior Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer Disclosure

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Constellation Pharmaceuticals Inc., A MorphoSys Company, CTI BioPharma Corp., Incyte Corporation, and Karyopharm Therapeutics Inc.

©2023 MediCom Worldwide, Inc., 4607 Library Rd., Ste. 220 #2001 · Bethel Park, PA 15102, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.